State of Alaska Department of Revenue Has $300,000 Stake in Enovis Co. (NYSE:ENOV)

State of Alaska Department of Revenue reduced its position in shares of Enovis Co. (NYSE:ENOV) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,367 shares of the company’s stock after selling 450 shares during the quarter. State of Alaska Department of Revenue’s holdings in Enovis were worth $300,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Enovis by 0.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,040,170 shares of the company’s stock worth $323,270,000 after acquiring an additional 30,198 shares during the period. BlackRock Inc. grew its holdings in Enovis by 4.9% during the 1st quarter. BlackRock Inc. now owns 5,174,172 shares of the company’s stock valued at $276,766,000 after buying an additional 241,816 shares during the last quarter. Vanguard Group Inc. grew its holdings in Enovis by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock valued at $258,242,000 after buying an additional 51,319 shares during the last quarter. Durable Capital Partners LP grew its holdings in Enovis by 1.3% during the 4th quarter. Durable Capital Partners LP now owns 2,714,032 shares of the company’s stock valued at $145,255,000 after buying an additional 34,825 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. grew its holdings in Enovis by 9.9% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock valued at $128,090,000 after buying an additional 219,659 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Trading Down 2.1 %

NYSE:ENOV opened at $58.55 on Friday. The business’s 50-day moving average is $60.65 and its two-hundred day moving average is $55.21. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16. Enovis Co. has a 12 month low of $43.04 and a 12 month high of $66.14. The firm has a market capitalization of $3.21 billion, a PE ratio of -95.98 and a beta of 1.97.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.76 by $0.03. The company had revenue of $455.00 million for the quarter, compared to analyst estimates of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The firm’s revenue was up 11.2% compared to the same quarter last year. During the same period last year, the company posted $0.72 earnings per share. Research analysts predict that Enovis Co. will post 2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on ENOV. Canaccord Genuity Group increased their target price on Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Wells Fargo & Company increased their target price on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Needham & Company LLC reiterated a “buy” rating and set a $82.00 target price on shares of Enovis in a report on Wednesday. UBS Group began coverage on Enovis in a research note on Monday, January 22nd. They set a “buy” rating and a $75.00 price target on the stock. Finally, William Blair began coverage on Enovis in a research report on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.